KR20220145871A - 암 치료 방법 - Google Patents

암 치료 방법 Download PDF

Info

Publication number
KR20220145871A
KR20220145871A KR1020227032892A KR20227032892A KR20220145871A KR 20220145871 A KR20220145871 A KR 20220145871A KR 1020227032892 A KR1020227032892 A KR 1020227032892A KR 20227032892 A KR20227032892 A KR 20227032892A KR 20220145871 A KR20220145871 A KR 20220145871A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
ser
cancer
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227032892A
Other languages
English (en)
Korean (ko)
Inventor
쉘리 에린 에커맨
마이클 앤. 알론소
데이빗 도르난
마르신 엘. 코와네츠
로버트 에스. 시코르스키
스티븐 에이. 스미스
Original Assignee
볼트 바이오테라퓨틱스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 볼트 바이오테라퓨틱스 인코퍼레이티드 filed Critical 볼트 바이오테라퓨틱스 인코퍼레이티드
Publication of KR20220145871A publication Critical patent/KR20220145871A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227032892A 2020-02-25 2021-02-25 암 치료 방법 Pending KR20220145871A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981355P 2020-02-25 2020-02-25
US62/981,355 2020-02-25
US202063105104P 2020-10-23 2020-10-23
US63/105,104 2020-10-23
PCT/US2021/019667 WO2021173832A1 (en) 2020-02-25 2021-02-25 Cancer treatment methods

Publications (1)

Publication Number Publication Date
KR20220145871A true KR20220145871A (ko) 2022-10-31

Family

ID=75143716

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227032892A Pending KR20220145871A (ko) 2020-02-25 2021-02-25 암 치료 방법

Country Status (7)

Country Link
US (1) US20230165968A1 (https=)
EP (1) EP4110403A1 (https=)
JP (1) JP2023519807A (https=)
KR (1) KR20220145871A (https=)
AU (1) AU2021226570A1 (https=)
CA (1) CA3169117A1 (https=)
WO (1) WO2021173832A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2024130003A1 (en) 2022-12-15 2024-06-20 Bolt Biotherapeutics, Inc. Cancer combination treatment method
CA3221817A1 (en) * 2023-06-30 2025-06-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Combination therapies for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
WO2007038720A2 (en) * 2005-09-27 2007-04-05 Coley Pharmaceutical Gmbh Modulation of tlr-mediated immune responses using adaptor oligonucleotides
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
WO2017087280A1 (en) * 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
KR20180134347A (ko) * 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
CN109843327B (zh) * 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
US20180271996A1 (en) * 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
CA3100544A1 (en) * 2018-05-17 2019-11-21 Bolt Biotherapeutics, Inc. Immunoconjugates
US20220152215A1 (en) * 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
US20220143012A1 (en) * 2019-03-15 2022-05-12 Bolt Biotherapeutics, Inc. Macromolecule-Supported TLR Agonists
WO2020190725A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220226491A1 (en) * 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting PD-L1
WO2020190731A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2

Also Published As

Publication number Publication date
US20230165968A1 (en) 2023-06-01
CA3169117A1 (en) 2021-09-02
JP2023519807A (ja) 2023-05-15
AU2021226570A1 (en) 2022-09-29
EP4110403A1 (en) 2023-01-04
WO2021173832A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
KR102777693B1 (ko) Claudin18 항체 및 암 치료 방법
CN114502592B (zh) 靶向cldn18.2的抗体及其制备方法和应用
EP3515945B1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and uses thereof
KR102679632B1 (ko) 신규한 항_cd137 항체 및 이의 용도
KR102776145B1 (ko) 항-bcma 폴리펩티드 및 단백질
KR20220145871A (ko) 암 치료 방법
TW202003561A (zh) 使用靶向4-1bb (cd137)之促效劑的組合療法
AU2017339711A1 (en) Bi specific anti-MUC16-CD3 antibodies and anti-MUC16 drug conjugates
JP2022525594A (ja) Ｈｅｒ２を標的とする免疫結合体
CN106459199A (zh) 抗‑egfrviii抗体及其用途
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
KR102634374B1 (ko) 항―ｏｘ４０ 항체 및 그의 용도
US11680102B2 (en) Anti-BAFF receptor antibodies and uses thereof
AU2021232158A1 (en) Anti-CD36 antibodies and their use to treat cancer
TW202345907A (zh) 抗gd2抗體、其免疫結合物及治療用途
CN118488964A (zh) 抗cd36抗体及其治疗癌症的用途
CN117355331A (zh) 抗Siglec组合物及其用途
WO2024130003A1 (en) Cancer combination treatment method
EP4725969A1 (en) Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
EA047699B1 (ru) Конъюгаты антитело-лекарственное средство, нацеленные на клаудин 18.2
EA044194B1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220921

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application